Seth Ettenberg

DataBiologics Can Help.

6

I am looking forward to moderating this cutting edge discussion with a panel of experts in the field of #AI in #medicalaffairs Luca Dezzani Herson Quiñones Sanjeev Welling Michael Vinegra #MASSEast #FierceMASS #MedicalAffairs #Technology #AI #GenerativeLangauge #FutureOfHealthcare #LifeSciences #Biotech #Pharma #FierceLifeSciences #WeAreFierce

62

3 Comments

The paper evaluated 6 modified Uridines - m5U, 5-methoxyuridine (mo5U), 5-hydroxylmethyluridine (hm5U), ψ, m1ψ, and N1 ethyl ψ (Et1ψ). All could be incorporated by T7 RNA polymerase and inhibited #mRNA immunogenicity. Et1ψ was found to hinder translation.

83

🚀🇺🇸 We are searching across the 🇺🇸 for leaders in 𝐓𝐂𝐑𝐬 and 𝐒𝐂/𝐒𝐩𝐚𝐭𝐢𝐚𝐥 Biology 📍 📍🌞𝑾𝒆𝒔𝒕 𝑪𝒐𝒂𝒔𝒕 👉 Rajan Bachra - Searching for a 𝐕𝐏 𝐢𝐧 𝐓𝐂𝐑 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 with direct experience in bringing these therapies 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐥𝐢𝐧𝐢𝐜 #IND 🔗https://lnkd.in/eY2-ETmE 📍🗽𝑬𝒂𝒔𝒕 𝑪𝒐𝒂𝒔𝒕  - Searching for a 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐢𝐚𝐧 with a breadth and depth of experience in #SingleCell and #SpatialTranscriptiomics 🔗https://lnkd.in/eaepu5i4 #Xenium #MERscope #spatialproteomics #CosMx #Visium, #smFISH #scRNAseq #TCRs #CART #CellTherapy Umbilical Life

17

4 Comments

Listen to David Segarnick, PhD discuss the Evolution in Biomarkers and Precision Medicine in Oncology. 🔬 The latest developments in using biomarkers to guide cancer treatment decisions. 🎯 Novel biomarkers for targeted therapies. 👩 Personalized medicine approaches in treatment resistant and refractory disease. Watch our #ASCO24 Key Findings and Missed Gems webinar here: https://lnkd.in/dju8fTaK #ASCO24 #DownloadableContent #Webinar #InizioMedical

16

Blood cancers like leukemia, lymphoma, and myeloma affect millions of people worldwide, yet many don’t fully understand the complexities of these diseases. Early detection, research, and personalized treatments are critical to improving outcomes for patients around the world. At Genomate Health, we are committed to advancing precision oncology by helping clinicians tailor treatments to each patient’s unique genetic and molecular profile. By leveraging cutting-edge technology, we’re working to ensure that blood cancer patients receive the most effective, personalized care possible. Join us in raising awareness, supporting research, and advocating for those battling blood cancer. Together, we can make a difference. #BloodCancerAwarenessMonth #PrecisionOncology #GenomateHealth

1

Call for proposals: Interest group sessions at the 2025 ASBMB Annual Meeting in April in Chicago! 🔬 Themes: ⏺️BMB education ⏺️#Cancer biology ⏺️Cell and developmental biology ⏺️Chemical biology ⏺️Computational biology, predictive technology and AI ⏺️DNA structure and function and RNA ⏺️Drug discovery and pharmacology ⏺️Enzyme chemistry and catalysis ⏺️Epigenetics and gene regulation ⏺️Glycobiology and extracellular matrices ⏺️Immunology ⏺️Lipids and membranes ⏺️Metabolism ⏺️Microbiology ⏺️Neurobiology ⏺️Plant biology and natural products ⏺️Protein structure, function and engineering ⏺️Proteomics and mass spectrometry ⏺️RNA ⏺️Signal transduction ☑️Eligibility: Submitter must be a regular, industry or early-career member of ASBMB. Learn more and submit your proposal here: https://lnkd.in/eRJQS-HW. 📅 Important Dates: ➡️Proposal deadline: Sept. 17 ➡️Notification of selection: Nov. 4 ➡️Speakers list due: Dec. 10 #ASBMB2025

2

Lundbeck, an innovator within CNS disorders and Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the companies have entered into a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. The agreement includes an upfront payment, performance-based milestones, and royalties. “Iambic’s state-of-the-art platform - including the NeuralPLexer protein-ligand structure prediction technology - will accelerate the generation of novel candidates with a higher probability of success at reaching our patients,” said Tarek Samad, PhD, Senior Vice President, and Head of Global Research at Lundbeck. “The pace at which Iambic can both design molecules in silico and then test them in the laboratory has the potential to unlock compelling neurology targets that have eluded traditional drug discovery methods.” “We welcome the opportunity to work with industry leaders at Lundbeck and to demonstrate the potential of the Iambic platform to discover neurological medicines,” said Thomas Miller, Ph.D., Chief Executive Officer, and co-founder of Iambic. Iambic is also developing an internal pipeline of candidates, discovered using its platform that integrates AI models for protein structure prediction and wholistic drug design with high-throughput chemistry and biology experimentation. Iambic’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs. This partnership reflects Lundbeck’s strong commitment to innovation across R&D. Merging the power of generative AI with expertise in developing drug candidates for brain diseases aims to significantly enhance the probability of success and reduce discovery timelines for novel therapeutics. The partnership also supports Lundbeck’s strategy of being a focused innovator in brain health. #AI #MachineLearning #Innovation #DrugDiscovery  #CNS #BrainHealth #Migraine #Partnership #Iambic #Lundbeck 

37

This review explores strategies to achieve organ-specific #mRNA delivery using #LNPs, including the discovery of new lipid structures, modification of targeting ligands, incorporation of additional components, and optimization of LNP formulations. 

166

2 Comments

Today in @ScienceMagazine, together with my former colleagues at the Novartis Institutes for BioMedical Research, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. Chemical Biologists may appreciate the CRBN-directed glue degrader library, here used in phenotypic screening of erythropoietic progenitors for HbF induction w/o effect on viability or differentiation. WIZ was discovered by proteomic study of hits and validated by CRISPR. Globin Biologists will enjoy the discovery of WIZ as a repressor of fetal hemoglobin (HbF). This biology has been intently studied, and here we find WIZ loss derepresses HbF by a local decrease in repressive H3K9me2, attributable to the association of WIZ and EHMT1/2. Medicinal chemists will appreciate the potent and selective activity of dWIZ-1 and dWIZ-2, the excellent drug-like properties, oral bioavailability and importantly the excellent tolerability in rodents and monkeys. For Biochemists, we show recruitment to CRBN as dependent on WIZ zinc finger 7, and biophysically characterize association by surface plasmon resonance. The CRBN:dWIZ: WIZ ternary complex buries 413 sq-A of surface area. Drug hunters like me might reflect on molecules that potently target a transcription factor with no pockets – effectively no tertiary structure predicted by @AlphaFold. This chemistry targets instead targets the ZnF secondary structure – truly marking the conceptual end of “undruggable” (if still in doubt). Hematologists will enjoy pharmacologic target validation in multiple pre-clinical models, a relatively selective impact on gene expression, the wide open therapeutic index, and the ease of end-game medicinal chemistry to produce investigational agents. Most importantly, for patients with Sickle Cell Disease. The advance of CRISPR-edited stem cells for transplantation, from our group and others, is a major advance. But patients need more accessible, safe, oral medicines especially in Sub-Saharan Africa. We welcome your feedback on this study, and hope dWIZ-1 and dWIZ-2 immediately prove valuable tools to the community and an inspiration for targeting disordered proteins. Finally, I thank all former colleagues in the NIBR TPD Initiative, and in particular this program’s true champion – Dr. Pamela Ting. Pam, working with you on this brave idea and on the collaborative assembly of the manuscript this last year are treasures I will always cherish, like our friendship. Article: https://lnkd.in/es6k87up Perspective: https://lnkd.in/ewn4eZNT

1,357

37 Comments

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

In vivo CART with CD8-LNP: exiting preclinical and toxicology results from small/large animal models. Very promising platform for autoimmune therapy.

11

The results from Arrowhead Pharmaceuticals' Phase 3 PALISADE study on plozasiran are truly impressive and could be a game-changer for patients with familial chylomicronemia syndrome (FCS). I'm excited by the potential impact this could have on a condition that currently has no approved treatments in the U.S. The involvement of experts like Gerald F. Watts and Bruce Given, M.D. adds significant weight to these findings. Their work not only showcases the power of RNAi therapeutics but also highlights how targeted innovation can meet critical, unmet medical needs. If plozasiran is approved, it could dramatically improve the quality of life for FCS patients, and it’s exciting to see this kind of progress in the field. #RNAi #FCS #research #Biotechnology

6

#Ang-2 correlated positively with BNP, cTnI, sCr, E/e′, and the extracellular water (ECW)/intracellular water (ICW) ratio (ECW/ICW). After 24 months, a deterioration in renal function was observed in 47 patients (58%). In multivariate regression analysis, both VCAM-1 and Ang-2 showed independent influences on risk of renal replacement therapy initiation. In a Kaplan-Meier analysis, 72% of patients with Ang-2 concentrations below the median (3.15 ng/mL) survived without dialysis for two years. Such an impact was not observed for GFR, VCAM, CCP, VEGF-C, or BTP. Endothelial activation, quantified by plasma levels of Ang-2, may play a key role in GFR decline and the need for dialysis initiation in patients with CKD 3b, 4, and 5. https://lnkd.in/dR-DBsRC

1

Work in the AAV gene therapy field? Get expert insight on a promising rare disease therapy in this article. #genetherapy #EPRTalks

3

Here's a summary of the #ADC-related abstracts for #SITC2024. 3 Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 ADC therapy Biocytogen Boston Corp 4 Establishing a tumor cell model to evaluate the bystander effect of ADC therapies Biocytogen Boston Corp 170 Identifying novel targets for ADCs in sarcomas using RNA sequencing BostonGene, Corp. 214 Decoding ADC-response in urothelial cancer with spatial multi-omics OMAPiX GmbH 313 ADCs as Adaptors for Universal CAR T cells University of Pittsburgh 629 Evaluation of immunomodulatory effects of ifinatamab deruxtecan (I-DXd) in the IDeate-Pantumor01 Phase 1/2 study in patients with advanced solid tumors Daiichi Sankyo 654 XMT-2056: A Phase 1 Study of a HER2-directed STING agonist ADC in HER2+ Solid Tumors The University of Texas MD Anderson Cancer Center 796 Enhanced in vitro T cell activation and cytotoxicity induced by a TROP2 ADC conjugated to the novel topoisomerase payload AZ14170133 in lung adenocarcinoma cells AstraZeneca 799 Vedotin ADCs Reinvigorate Anti-Tumor Immunity in a Preclinical Model of Anti-PD1 Resistance Pfizer 807 The PD1-TIM3 bispecific antibody sabestomig combines with a topoisomerase 1 inhibitor-conjugated ADC for additive anti-tumor activity and tumor immune modulation in a novel humanized NSCLC mouse model AstraZeneca 1017 PSMA-E7766 ADC: Harnessing targeted delivery of STING agonists for anti-tumor activity in prostate cancer Eisai Co., Ltd. 1045 PF-08046032: A novel, investigational CD25-directed ADC optimized for selective depletion of regulatory T cells in advanced malignant tumors Pfizer 1048 A differentiated cMet x EGFR bispecific ADC demonstrated broad antitumor activity and promising safety profile in preclinical models EpimAb Biotherapeutics, Inc. 1049 TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development Biocytogen Pharmaceuticals 1050 Comprehensive Characterization of ADCs for Screening and Manufacturing ACROBiosystems 1051 LNCB74 is a B7-H4 targeting antibody-drug-conjugate with a β-glucuronide linker-MMAE payload system to enhance the therapeutic index in B7-H4 expressing cancers. NextCure, Inc. 1053 XMT-2056, a HER2-targeted Immunosynthen STING agonist ADC, induces anti-tumor activity at low doses in preclinical models Mersana Therapeutics 1054 Developing a Gold-based ADC for Synovial Sarcoma Brigham Young University 1056 IPH45, a next-generation ADC targeting Nectin-4 Innate Pharma 1303 ADC payload-induced IL1 suggests potential for anti-IL1RAP therapy combination for enhanced treatment efficacy and prevention of neuropathy Cantargia AB 1426 The anti-tumor activity of a novel anti-Her2/anti-Trop2 bispecific VHH ADC Bright Biologics LLC This posting summarizes the ADC-related abstracts, covering various aspects of ADC research, including preclinical models, combination therapies, novel targets, and clinical studies.

10

2 Comments

Strategies to prevent and manage antibody-drug conjugate-associated nausea and vomiting https://lnkd.in/dyJfwuVt Sarah Cannon Research Institute Erika Hamilton, MD PeerVoice #Cancer #CancerResearch #Nausea #Vomiting #CancerTreatment #BreastCancer #Medicine #Health #Oncology #OncoDaily

16